MELPHALAN

Myeloproliferative Neoplasm

Center for International Blood and Marrow Transplant ResearchSmall moleculePhase 2/3Active

BBB

72/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 67/ 100
Competitive Position: 81/ 100

Competitive context

69 Active assets in the Myeloproliferative Neoplasm cohort.

Asset / Sponsor	Phase	Rating
Fludarabine Sawa Ito, MD	Phase 4	BB
ANTI-HUMAN T-LYMPHOCYTE IMMUNOGLOBULIN, RABBIT Fred Hutchinson Cancer Center	Phase 2/3	BB
Romidepsin Sawa Ito, MD	Phase 4	BB
FILGRASTIM City of Hope Medical Center	Phase 3	BB
Busulphan Sawa Ito, MD	Phase 4	BB

View all 50 →

Same molecule, other indications

MELPHALAN is also rated in:

diffuse large B-cell lymphomaActive

BBB

Indicative · Phase 4

76 / 100

myelodysplastic/myeloproliferative neoplasmActive

BBB

Indicative · Phase 2/3

76 / 100

cancer of unknown primary siteDormant

BBB

Indicative · Phase 2/3

72 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.